Dr. Michael Alexander Joins Galaxy Therapeutics as Chief Medical Officer Galaxy Therapeutics welcomes Dr. Michael Alexander as Chief Medical Officer, enhancing its leadership for innovative brain aneurysm treatments.

Dr. Michael Alexander Joins Galaxy Therapeutics as Chief Medical Officer #United_States #Milpitas #Galaxy_Therapeutics #SEAL_device #Dr._Michael_Alexander

Galaxy Therapeutics Announces Completion of Primary Cohort Enrollment in SEAL IT IDE Trial Galaxy Therapeutics has successfully finished enrolling patients for the primary cohort of its pivotal SEAL IT IDE trial, marking significant progress in treating brain aneurysms.

Galaxy Therapeutics Announces Completion of Primary Cohort Enrollment in SEAL IT IDE Trial #United_States #Milpitas #Galaxy_Therapeutics #SEAL_device #brain_aneurysms